10315-07-8

Basic information

• Product Name: 1-BENZYLPIPERIDINE-4-CARBOXYLIC ACID
• Synonyms: BUTTPARK 33\04-90;1-BENZYL-ISONIPECOTIC ACID;1-BENZYLPIPERIDINE-4-CARBOXYLIC ACID;1-BENZYL-4-PIPERIDINE CARBOXYLIC ACID;N-BENZYL-ISONIPECOTIC ACID;1-(phenylmethyl)-4-Piperidinecarboxylic acid;N-Benzylpiperidine-4-carboxylic acid;1-benzylpiperidin-4-carboxylic acid
• CAS NO: 10315-07-8
• Molecular Formula: C₁₃H₁₇NO₂
• Molecular Weight: 219.28
• Product Categories: pharmacetical;Carboxylic Acids;Pyrans, Piperidines &Piperazines;Carboxylic Acids;Pyrans, Piperidines & Piperazines
• Mol File: 10315-07-8.mol
• Article Data: 18

Chemical Properties

• Melting Point: 169.0-170.5 °C
• Boiling Point: 358.584 °C at 760 mmHg
• Flash Point: 170.666 °C
• Appearance: /
• Density: 1.165
• Vapor Pressure: 9.13E-06mmHg at 25°C
• Refractive Index: 1.572
• Storage Temp.: 2-8°C
• PKA: 4.02±0.20(Predicted)
• CAS DataBase Reference: 1-BENZYLPIPERIDINE-4-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BENZYLPIPERIDINE-4-CARBOXYLIC ACID(10315-07-8)
• EPA Substance Registry System: 1-BENZYLPIPERIDINE-4-CARBOXYLIC ACID(10315-07-8)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• Hazardous Substances Data: 10315-07-8(Hazardous Substances Data)

Usage

General Description

1-BENZYLPIPERIDINE-4-CARBOXYLIC ACID is a chemical compound with the molecular formula C15H19NO2. It is a carboxylic acid derivative of benzylpiperidine, a heterocyclic compound. This chemical has applications in the pharmaceutical industry as it is used in the synthesis of various important drugs, especially as a precursor in the production of medicines for central nervous system disorders and neuropsychiatric conditions. It is also used as a building block in the preparation of other organic compounds. Its structure and properties make it a valuable chemical for drug discovery and development, as well as for academic and industrial research purposes.

InChI:InChI=1/C13H17NO2/c15-13(16)12-6-8-14(9-7-12)10-11-4-2-1-3-5-11/h1-5,12H,6-10H2,(H,15,16)

Upstream product

• 123-91-1 1,4-dioxane 
• 24228-40-8 N-benzyl isonipecotic acid ethyl ester 
• 66-99-9 β-naphthaldehyde 
• 498-94-2 isonipecotic acid 
• 7462-86-4 methyl piperidine-4-carboxylate hydrochloride 
• 100-39-0 benzyl bromide 
• 10315-06-7 1-benzylpiperidine-4-carboxylic acid methyl ester 
• 2971-79-1 isonipecotic acid methyl ester 
• 100-44-7 benzyl chloride 
• 1126-09-6 4-carbethoxypiperidine 

Downstream Products

• 914226-80-5 1-benzyl-N-isopropylpiperidine-4-carboxamide 
• 1415992-30-1 1-benzyl-N-(5-bromo-2-hydroxyphenyl)piperidine-4-carboxamide 
• 1415992-31-2 2-(1-benzylpiperidin-4-yl)-5-bromobenzo[d]oxazole 
• 1401728-91-3 1-benzyl-4-(1-methyl-1H-tetrazol-5-yl)piperidine 
• 280111-63-9 1-benzylpiperidine-4-carboxylic acid methylamide 
• 301219-96-5 1-benzyl-N-methoxy-N-methylpiperidine-4-carboxamide 
• 22065-85-6 N-benzyl-4-formylpiperidine 
• 88915-26-8 4-aminomethyl-1-benzylpiperidine 

Relevant articles and documents

Novel N-benzylpiperidine carboxamide derivatives as potential cholinesterase inhibitors for the treatment of Alzheimer's disease

A series of fifteen acetylcholinesterase inhibitors were designed and synthesised based upon the previously identified lead compound 5,6-dimethoxy-1-oxo-2,3-dihydro-1H-inden-2-yl 1-benzylpiperidine-4-carboxylate (5) which showed good inhibitory activity (IC50 0.03 ± 0.07 μM) against acetylcholinesterase. A series of compounds were prepared wherein the ester linker in the original lead compound was exchanged for a more metabolically stable amide linker and the indanone moiety was exchanged for a range of aryl and aromatic heterocycles. The two most active analogues 1-benzyl-N-(5,6-dimethoxy-8H-indeno[1,2-d]thiazol-2-yl)piperidine-4-carboxamide (28) and 1-benzyl-N-(1-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl) piperidine-4-carboxamide (20) afforded in vitro IC50 values of 0.41 ± 1.25 and 5.94 ± 1.08 μM, respectively. In silico screening predicts that 20 will be a blood brain-barrier permeant, and molecular dynamic simulations are indicative of a close correlation between the binding of 20 and the Food and Drug Administration-approved cholinesterase inhibitor donepezil (1).

4,5-dimethoxy-2-nitrobenzohydrazides and 1-(1-benzylpiperidin-4-yl)ethan-1-ones as potential antioxidant/cholinergic endowed small molecule leads

The objective of this research is to generate leads for developing our ultimate poly-active molecules with utility in central nervous system (CNS) diseases. Indeed, poly-active molecules capable of mitigating brain free radical damage while enhancing acetylcholine signaling (via cholinesterase inhibition) are still being sought for combating Alzheimer’s disease (AD). We differentiate “poly-active” agents from “multi-target” ones by defining them as single molecular entities designed to target only specific contributory synergistic pharmacologies in a disease. For instance, in AD, free radicals either initiate or act in synergy with other pharmacologies, leading to disease worsening. For this preliminary report, a total of 14 (i.e., 4,5-dimethoxy-2-nitrobenzohydrazide plus 1-(1-benzylpiperidin-4-yl)ethan-1-one) derivatives were synthesized and screened, in silico and in vitro, for their ability to scavenge free radicals and inhibit acetylcholinesterase (AChE)/butyrylcholinesterase (BuChE) enzymes. Overall, six derivatives (4a, 4d, 4e, 4f, 4g, 9b) exhibited potent (>30%) antioxidant properties in the oxygen radical absorbance capacity (ORAC) assay. The antioxidant values were either comparable or more potent than the comparator molecules (ascorbic acid, resveratrol, and trolox). Only three compounds (4d, 9a, 9c) yielded modest AChE/BuChE inhibitions (>10%). Please note that a SciFinder substance data base search confirmed that most of the compounds reported herein are new, except 9a and 9c which are also commercially available.

NOVEL GPR119 AGONIST COMPOUNDS

The present invention relates to novel compounds of formula (I), process for preparation of the same and composition comprising these compounds.